Tobacco Use after Cancer Diagnosis


Studies comparing cancer patients who smoke cigarettes at the time of diagnosis to former or never smokers have demonstrated increased difficulty with surgical wound healing and more treatment morbidity; reduced radiation and chemotherapy efficacy; reduced time to recurrence, progression, and second primary cancers; and increased mortality. Many research questions remain to be addressed related to tobacco use by cancer patients, but research in this area is impeded by inadequate assessment of tobacco use after cancer diagnosis and a lack of valid, harmonized measures that are tailored to the trajectory of cancer diagnosis, treatment and survivorship.

To facilitate research in this area, NCI has partnered with the American Association for Cancer Research (AACR) to form the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force (PDF). The Task Force developed measures Exit Disclaimer that have undergone clinical testing and are now available for use in all cancer research. Visit the Tobacco Use by Cancer Patients workspace Exit Disclaimer at Exit Disclaimer to access the latest information and updates.

Cancer Patient Tobacco Use Questionnaire (C-TUQ) Fact Sheet (PDF, 1.1 MB), February 2018

Findings from the Task Force on recommended measures, protocol for measurement, and priority research areas:

Funding Opportunities

View all Tobacco Control Funding Opportunities.




Stephanie Land, Ph.D.

Glen Morgan, Ph.D.